ECG-guided Immediate Primary PCI for Culprit Vessel to Reduce Door to Device Time
Launched by BEIJING LUHE HOSPITAL · Sep 1, 2017
Trial Information
Current as of July 23, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient must be \> 18 years of age
- • Patients have typical chest pain for at least 20 minutes and have ECG changes typical for STEMI (ST elevation≥2mm in two continuous precordial leads or ST elevations≥1mm in two limb leads or new left bundle branch block) or ECG changes compatible with true posterior MI
- • Symptoms ≥ 30 min and ≤12 hours
- • Patient and treating interventional cardiologist agree for randomization
- • Patient provides written informed consent
- • Diagnostic and therapeutic intervention performed through transradial artery approach
- • Palpable radial artery.
- Exclusion Criteria:
- • Concurrent participation in other investigational study
- • Current platelet count \<100 x 10\^9cells/L or Hgb \<10 g/dL
- • Absence of radial artery pulsation
- • Active bleeding or significant increased risk of bleeding, severe hepatic insufficiency, current peptic ulceration, proliferative diabetic retinopathy
- • Uncontrolled hypertension
- • Prior CABG surgery
- • Fibrinolytic therapy for current MI treatment
- • patient have a life expectancy of \<180days
About Beijing Luhe Hospital
Beijing Luhe Hospital, a leading medical institution in China, is dedicated to advancing healthcare through innovative clinical research and trials. With a strong emphasis on patient-centered care, the hospital integrates cutting-edge medical technology and comprehensive clinical services to enhance treatment outcomes. Its robust research programs focus on a variety of therapeutic areas, striving to contribute to the global medical community by developing safe and effective interventions. The hospital's commitment to excellence in clinical research is reflected in its collaboration with various academic and industry partners, fostering an environment that promotes scientific discovery and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials